Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer

医学 内科学 乳腺癌 安慰剂 二甲双胍 肿瘤科 癌症 妇科 胰岛素 病理 替代医学
作者
Pamela J. Goodwin,Bingshu E. Chen,Karen A. Gelmon,Timothy J. Whelan,Marguerite Ennis,Julie Lemieux,Jennifer A. Ligibel,Dawn L. Hershman,Ingrid A. Mayer,Timothy J. Hobday,Judith M. Bliss,Priya Rastogi,Manuela Rabaglio,Som D. Mukherjee,John R. Mackey,Vandana G. Abramson,Conrad D. Oja,Robert Wesolowski,Alastair M. Thompson,Daniel Rea
出处
期刊:JAMA [American Medical Association]
卷期号:327 (20): 1963-1963 被引量:148
标识
DOI:10.1001/jama.2022.6147
摘要

Importance

Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies.

Objective

To determine whether the administration of adjuvant metformin (vs placebo) to patients with breast cancer without diabetes improves outcomes.

Design, Setting, and Participants

MA.32, a phase 3 randomized, placebo-controlled, double-blind trial, conducted in Canada, Switzerland, US, and UK, enrolled 3649 patients with high-risk nonmetastatic breast cancer receiving standard therapy between August 2010 and March 2013, with follow-up to October 2020.

Interventions

Patients were randomized (stratified for hormone receptor [estrogen receptor and/or progesterone receptor {ER/PgR}] status, positive vs negative; body mass index, ≤30 vs >30; human epidermal growth factor receptor 2 [ERBB2,formerlyHER2orHER2/neu], positive vs negative; and any vs no chemotherapy) to 850 mg of oral metformin twice a day (n = 1824) or oral placebo twice a day (n = 1825) for 5 years.

Main Outcomes and Measures

The primary outcome was invasive disease–free survival in hormone receptor–positive breast cancer. Of the 8 secondary outcomes, overall survival, distant relapse–free survival, and breast cancer–free interval were analyzed.

Results

Of the 3649 randomized patients (mean age, 52.4 years; 3643 women [99.8%]), all (100%) were included in analyses. After a second interim analysis, futility was declared for patients who were ER/PgR−, so the primary analysis was conducted for 2533 patients who were ER/PgR+. The median duration of follow-up in the ER/PgR+ group was 96.2 months (range, 0.2-121 months). Invasive disease–free survival events occurred in 465 patients who were ER/PgR+. The incidence rates for invasive disease–free survival events were 2.78 per 100 patient-years in the metformin group vs 2.74 per 100 patient-years in the placebo group (hazard ratio [HR], 1.01; 95% CI, 0.84-1.21;P = .93), and the incidence rates for death were 1.46 per 100 patient-years in the metformin group vs 1.32 per 100 patient-years in the placebo group (HR, 1.10; 95% CI, 0.86-1.41;P = .47). Among patients who were ER/PgR−, followed up for a median of 94.1 months, incidence of invasive disease–free survival events was 3.58 vs 3.60 per 100 patient-years, respectively (HR, 1.01; 95% CI, 0.79-1.30;P = .92). None of the 3 secondary outcomes analyzed in the ER/PgR+ group had statistically significant differences. Grade 3 nonhematological toxic events occurred more frequently in patients taking metformin than in patients taking placebo (21.5% vs 17.5%, respectively,P = .003). The most common grade 3 or higher adverse events in the metformin vs placebo groups were hypertension (2.4% vs 1.9%), irregular menses (1.5% vs 1.4%), and diarrhea (1.9% vs 7.0%).

Conclusions and Relevance

Among patients with high-risk operable breast cancer without diabetes, the addition of metformin vs placebo to standard breast cancer treatment did not significantly improve invasive disease–free survival.

Trial Registration

ClinicalTrials.gov Identifier: NCT01101438
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
文欣完成签到 ,获得积分10
刚刚
谷蓝完成签到,获得积分10
刚刚
大方的觅海完成签到,获得积分10
刚刚
Bean发布了新的文献求助10
刚刚
可乐发布了新的文献求助10
1秒前
卜懂得完成签到,获得积分10
1秒前
1秒前
孟德尔吃豌豆完成签到,获得积分10
2秒前
江宜完成签到 ,获得积分10
3秒前
4秒前
张岱帅z完成签到,获得积分10
4秒前
4秒前
sheep完成签到,获得积分10
4秒前
木子木子李完成签到,获得积分10
5秒前
景妙海完成签到 ,获得积分10
6秒前
心心完成签到,获得积分10
6秒前
CY03完成签到,获得积分10
8秒前
taoze完成签到,获得积分10
8秒前
张小度ever完成签到 ,获得积分10
9秒前
hutian完成签到,获得积分10
9秒前
大姿兰卡眼睛完成签到 ,获得积分10
10秒前
Sky完成签到,获得积分10
11秒前
静静子完成签到,获得积分10
11秒前
随安完成签到,获得积分20
11秒前
大意的雨双完成签到 ,获得积分10
11秒前
Dr.Shan完成签到,获得积分10
11秒前
JIASHOUSHOU完成签到,获得积分10
12秒前
一颗煤炭完成签到 ,获得积分10
12秒前
Cipher完成签到 ,获得积分10
13秒前
脑洞疼应助LIUYONG采纳,获得10
13秒前
可乐完成签到,获得积分10
13秒前
14秒前
koukousang完成签到,获得积分10
15秒前
乐乐应助张无缺采纳,获得10
16秒前
三三完成签到,获得积分10
16秒前
平常荷花完成签到 ,获得积分10
18秒前
量子星尘发布了新的文献求助10
19秒前
阿胡发布了新的文献求助30
19秒前
水晶李完成签到 ,获得积分10
20秒前
脑洞疼应助静静子采纳,获得100
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029